ଟେରାଜୋସିନ

ଟେରାଜୋସିନ
Clinical data
Trade names	Hytrin, Zayasel, others
Synonyms	[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-tetrahydrofuran-2-yl-methanone
AHFS/Drugs.com	monograph
MedlinePlus	a693046
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Protein binding	90-94%
Elimination half-life	12 hours
Identifiers
	IUPAC name (RS)-6,7-Dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine;
ECHA InfoCard	100.118.191
Chemical and physical data
Formula	C19H25N5O4
Molar mass	୩୮୭.୪୪ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N3CCN(c2nc1cc(OC)c(OC)cc1c(n2)N)CC3)C4OCCC4;
	InChI InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22) ; Key:VCKUSRYTPJJLNI-UHFFFAOYSA-N ;
(verify)

ଟେରାଜୋସିନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ହାଇଟ୍ରିନ୍, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଏକ ବର୍ଦ୍ଧିତ ପ୍ରୋଷ୍ଟେଟର ଲକ୍ଷଣ ଏବଂ ଉଚ୍ଚ ରକ୍ତଚାପର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ | ^[୧] ଉଚ୍ଚ ରକ୍ତଚାପ ପାଇଁ ଏହା ଏକ କମ୍ ପସନ୍ଦଯୋଗ୍ୟ ବିକଳ୍ପ | ^[୨] ଏହା ପାଟିରେ ଦିଆଯାଏ | ^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡ ବୁଲାଇବା, ମୁଣ୍ଡବିନ୍ଧା, ଥକାପଣ, ଫୁଲା, ବାନ୍ତି, ଏବଂ ଠିଆ ହେବା ସମୟରେ ନିମ୍ନ ରକ୍ତଚାପ ହୋଇପାରେ | ^[୧] ଗୁରୁତର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ପ୍ରିଆପିଜିମ୍ ଏବଂ ନିମ୍ନ ରକ୍ତଚାପ ହୋଇପାରେ | ^[୨] ଚିକିତ୍ସା ଆରମ୍ଭ ପୂର୍ବରୁ ପ୍ରୋଷ୍ଟେଟ କର୍କଟକୁ ଏଡ଼ାଇ ଦିଆଯିବା ଉଚିତ୍। ^[୨] ଏହା ଏକ ଆଲଫା-୧ ବ୍ଲକର ଅଟେ ଏବଂ ରକ୍ତନଳୀମାନଙ୍କୁ ଶିଥିଳ କରି ଏବଂ ମୂତ୍ରାଶୟ ମୁହଁ ଖୋଲିଦେଇ କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ | ^[୨]

୧୯୭୫ ମସିହାରେ ଟେରାଜୋସିନ ପେଟେଣ୍ଟ୍ ହୋଇଥିଲେ ଏବଂ ୧୯୮୫ରେ ଡାକ୍ତରୀ ବ୍ୟବହାରରେ ଆସିଥିଲା ^[୩] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ | ^[୪] ଯୁକ୍ତରାଜ୍ୟରେ ଏକ ମାସର ଯୋଗାଣ ୨୦୨୧ ସୁଦ୍ଧା ମୂଲ୍ୟ ୫ ପାଉଣ୍ଡ ଥିଲା । ^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ହୋଲସେଲ ମୂଲ୍ୟ ୨୦୧୨ସୁଦ୍ଧା ପ୍ରାୟ ୪.୫୦ ଆମେରିକୀୟ ଡଲାର ଅଟେ। ^[୬] ୨୦୧୭ରେ, ଏହା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୧୯୪ ତମ ସାଧାରଣତ ପ୍ରେସକ୍ରିପସନ୍ ଔଷଧ ଥିଲା, ଯେଉଁଥିରେ ଦୁଇ ଲକ୍ଷରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ୍ ରହିଥିଲା। ^[୭] ^[୮]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Terazosin Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 7 August 2020. Retrieved 17 March 2019.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ "Terazosin Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 7 August 2020. Retrieved 17 March 2019.
↑ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 455. ISBN 9783527607495. Archived from the original on 2019-12-22. Retrieved 2019-02-28.
↑ "7. Genito-urinary system". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. p. 833. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)
↑ "7. Genito-urinary system". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. p. 833. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)
↑ "NADAC". Centers for Medicare and Medicaid Services. 27 February 2019. Archived from the original on 2019-03-06. Retrieved 2019-03-17.
↑ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
↑ "Terazosin - Drug Usage Statistics". ClinCalc. Archived from the original on 8 October 2020. Retrieved 11 April 2020.

[AHFS2019-1] ୧.୦ ^୧.୧ "Terazosin Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 7 August 2020. Retrieved 17 March 2019.

[autogen2-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ "Terazosin Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 7 August 2020. Retrieved 17 March 2019.

[3] Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 455. ISBN 9783527607495. Archived from the original on 2019-12-22. Retrieved 2019-02-28.

[BNF82-4] "7. Genito-urinary system". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. p. 833. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)

[autogen3-5] "7. Genito-urinary system". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. p. 833. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)

[NADAC2019-6] "NADAC". Centers for Medicare and Medicaid Services. 27 February 2019. Archived from the original on 2019-03-06. Retrieved 2019-03-17.

[ref-7] "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.

[ref1-8] "Terazosin - Drug Usage Statistics". ClinCalc. Archived from the original on 8 October 2020. Retrieved 11 April 2020.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]